Dongrong Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dongrong Yu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- De Jin
Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, China
4 shared publications - Caifeng Zhu
Department of Nephrology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou 310007, Zhejiang, China
3 shared publications - Jin Yu
Department of Nephrology (Key Laboratory of Kidney Disease Prevention and Control Technology), Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University
3 shared publications Jun Ni
Department of Nephrology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (HangZhou Hospital of Traditional Chinese Medicine), China
3 shared publicationsCan Yu
Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, China
2 shared publicationsEnhui Chen
Department of Nephrology, Zhejiang Chinese Medical University, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in BMC Endocrine Disorders
Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease: a single-center retrospective cohort study
- 12 October 2026
- Published by Springer Nature in BMC Endocrine Disorders
Open AccessClinical characteristics and prognosis of non-albuminuric diabetic kidney disease: a single-center retrospective cohort study
- Open Access
- 20 July 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1) , 115
Cardiac effects of prolonged recombinant human interleukin-11 treatment in severe thrombocytopenia: a retrospective cohort study
Background: Recombinant human interleukin-11 (rhIL-11) is commonly used to treat thrombocytopenia induced by cancer chemotherapy. However, concerns about its potential cardiac side effects, especially with prolonged use, warrant further investigation. Aim: This study aimed to evaluate the cardiac effects of prolonged rhIL-11 use by comparing changes in cardiac biomarkers and arrhythmia rates between rhIL-11 and recombinant human thrombopoietin (rhTPO) in patients with severe thrombocytopenia. Method: We conducted a retrospective cohort study of adult patients treated with rhIL-11 or rhTPO for ≥ 5 days between 2015 and 2021. Data were collected at baseline, during treatment, and after discontinuation, focusing on BNP levels and arrhythmia occurrences. Statistical analyses were performed to compare the outcomes between the two groups. Results: Our study cohort comprised 23 patients treated with rhIL-11 and 7 patients receiving rhTPO. The rhIL-11 group showed a significant increase in serum BNP levels from a baseline median of 418 pg/mL (IQR: 193–1205) to 3084 pg/mL (IQR: 1446–5000) within one week ( P < 0.01), while the rhTPO group had no significant changes ( P = NS). BNP levels in the rhIL-11 group decreased to 384.0 pg/mL (IQR: 239.0–460.0) one week post-discontinuation ( P < 0.05). Cardiac arrhythmias were documented in 34.8% (8/23) of rhIL-11-treated patients, demonstrating a clear treatment duration-dependent pattern: 83.3% (5/6) of patients receiving rhIL-11 for more than two weeks developed arrhythmias, with all 3 patients (100%) treated beyond three weeks experiencing cardiac complications, including two cases of frequent ventricular tachycardia. The rhTPO group showed no significant BNP changes or arrhythmic events. Kaplan-Meier survival analysis revealed a statistically significant divergence in arrhythmia risk profiles between the two treatment groups ( P < 0.05). Multivariate COX regression analysis identified age as an independent risk factor for arrhythmia development (HR 1.071, 95% CI: 1.007–1.139; p = 0.029). Conclusions: Prolonged rhIL-11 treatment was associated with significant elevations in BNP levels and a higher incidence of arrhythmias, particularly with longer treatment durations. These findings highlight the need for close cardiac monitoring in patients receiving extended rhIL-11 therapy. Further large-scale, prospective studies are necessary to establish clear cardiac safety guidelines for rhIL-11 use.
- 20 July 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1) , 115
Open AccessCardiac effects of prolonged recombinant human interleukin-11 treatment in severe thrombocytopenia: a retrospective cohort study
Background: Recombinant human interleukin-11 (rhIL-11) is commonly used to treat thrombocytopenia induced by cancer chemotherapy. However, concerns about its potential cardiac side effects, especially with prolonged use, warrant further investigation. Aim: This study aimed to evaluate the cardiac effects of prolonged rhIL-11 use by comparing changes in cardiac biomarkers and arrhythmia rates between rhIL-11 and recombinant human thrombopoietin (rhTPO) in patients with severe thrombocytopenia. Method: We conducted a retrospective cohort study of adult patients treated with rhIL-11 or rhTPO for ≥ 5 days between 2015 and 2021. Data were collected at baseline, during treatment, and after discontinuation, focusing on BNP levels and arrhythmia occurrences. Statistical analyses were performed to compare the outcomes between the two groups. Results: Our study cohort comprised 23 patients treated with rhIL-11 and 7 patients receiving rhTPO. The rhIL-11 group showed a significant increase in serum BNP levels from a baseline median of 418 pg/mL (IQR: 193–1205) to 3084 pg/mL (IQR: 1446–5000) within one week ( P < 0.01), while the rhTPO group had no significant changes ( P = NS). BNP levels in the rhIL-11 group decreased to 384.0 pg/mL (IQR: 239.0–460.0) one week post-discontinuation ( P < 0.05). Cardiac arrhythmias were documented in 34.8% (8/23) of rhIL-11-treated patients, demonstrating a clear treatment duration-dependent pattern: 83.3% (5/6) of patients receiving rhIL-11 for more than two weeks developed arrhythmias, with all 3 patients (100%) treated beyond three weeks experiencing cardiac complications, including two cases of frequent ventricular tachycardia. The rhTPO group showed no significant BNP changes or arrhythmic events. Kaplan-Meier survival analysis revealed a statistically significant divergence in arrhythmia risk profiles between the two treatment groups ( P < 0.05). Multivariate COX regression analysis identified age as an independent risk factor for arrhythmia development (HR 1.071, 95% CI: 1.007–1.139; p = 0.029). Conclusions: Prolonged rhIL-11 treatment was associated with significant elevations in BNP levels and a higher incidence of arrhythmias, particularly with longer treatment durations. These findings highlight the need for close cardiac monitoring in patients receiving extended rhIL-11 therapy. Further large-scale, prospective studies are necessary to establish clear cardiac safety guidelines for rhIL-11 use.
- 24 February 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (4) , 1801-1810
Causal relationship between mental illness and venous thromboembolism: a Mendelian randomization study
- 24 February 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (4) , 1801-1810
Causal relationship between mental illness and venous thromboembolism: a Mendelian randomization study
- Open Access
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16
Case Report: UMOD gene mutation and phenotypic overlap with REN in autosomal dominant tubulointerstitial kidney disease
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare monogenic kidney disorder characterized by progressive tubular atrophy and interstitial fibrosis. It is primarily associated with pathogenic variants in genes such as UMOD (uromodulin), REN (renin), MUC1 (mucin 1), and HNF1B (hepatocyte nuclear factor 1-beta). We report a unique Chinese case of ADTKD-UMOD in a patient carrying a UMOD gene mutation. The clinical presentation was complex: in addition to the classic features of UMOD mutations (hyperuricemia and gout), the patient exhibited endocrine and metabolic abnormalities typically linked to REN gene defects (ADTKD-REN), including anemia, hypotension, and hyporeninemic hypoaldosteronism. However, renal biopsy and genetic testing ultimately confirmed the diagnosis as ADTKD caused by a heterozygous missense mutation in UMOD gene.
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16
Open AccessCase Report: UMOD gene mutation and phenotypic overlap with REN in autosomal dominant tubulointerstitial kidney disease
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare monogenic kidney disorder characterized by progressive tubular atrophy and interstitial fibrosis. It is primarily associated with pathogenic variants in genes such as UMOD (uromodulin), REN (renin), MUC1 (mucin 1), and HNF1B (hepatocyte nuclear factor 1-beta). We report a unique Chinese case of ADTKD-UMOD in a patient carrying a UMOD gene mutation. The clinical presentation was complex: in addition to the classic features of UMOD mutations (hyperuricemia and gout), the patient exhibited endocrine and metabolic abnormalities typically linked to REN gene defects (ADTKD-REN), including anemia, hypotension, and hyporeninemic hypoaldosteronism. However, renal biopsy and genetic testing ultimately confirmed the diagnosis as ADTKD caused by a heterozygous missense mutation in UMOD gene.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 6269-6282
Integrative Network Pharmacology and Transcriptomics Reveal the Mechanism of Gui-Qi-Yi-Shen Granules in the Treatment of IgA Nephropathy
Background: IgA nephropathy (IgAN) is a significant contributor to kidney failure and death, with limited therapeutic options. Gui-qi-yi-shen (GQYS) granules are a classic Chinese medicine prescription for treating IgAN. Nevertheless, the underlying molecular mechanism is still unclear. Purpose: To elucidate the mechanism by which GQYS exerts its therapeutic effects in IgAN treatment. Materials and Methods: Itgam-IRES-hCD89 mice (eight-week-old) were divided into four groups: IgAN, low-dose GQYS (GQYS-L, 5.2 g/kg), high-dose GQYS (GQYS-H, 10.4 g/kg), and Losartan (6.5 mg/kg). Coincident C57/BL6 mice were used as controls. Periodic acid-Schiff (PAS) staining, biochemical analyses, and immunofluorescence (IF) were used for therapeutic evaluation. Network pharmacology and transcriptomic analyses were performed to investigate the potential mechanisms of GQYS, while Western blotting and IF were performed to confirm these actions. Results: Compared to the model group, 24 h proteinuria and alanine aminotransferase levels were significantly reduced in the GQYS groups. PAS staining showed that IgAN mice exhibited glomerular mesangial hypercellularity as well as matrix expansion, whereas these pathologies were alleviated in the GQYS groups. IF results revealed that GQYS reduced deposition of IgA and C3 in the glomerular mesangial areas compared to that in the model mice. Network pharmacology and transcriptomic analyses identified genes and pathways that may be associated with the effects of GQYS against IgAN. Western blotting and IF results indicated GQYS attenuated the expression of TLR4/MyD88/NF-kB and IL-6/JAK2/STAT3 signaling pathway related proteins. Conclusion: GQYS reduced proteinuria and ameliorate renal pathological damage in IgAN via TLR4/MyD88/NF-kB and IL-6/JAK2/STAT3 signaling, offering a promising therapeutic strategy.
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 6269-6282
Open AccessIntegrative Network Pharmacology and Transcriptomics Reveal the Mechanism of Gui-Qi-Yi-Shen Granules in the Treatment of IgA Nephropathy
Background: IgA nephropathy (IgAN) is a significant contributor to kidney failure and death, with limited therapeutic options. Gui-qi-yi-shen (GQYS) granules are a classic Chinese medicine prescription for treating IgAN. Nevertheless, the underlying molecular mechanism is still unclear. Purpose: To elucidate the mechanism by which GQYS exerts its therapeutic effects in IgAN treatment. Materials and Methods: Itgam-IRES-hCD89 mice (eight-week-old) were divided into four groups: IgAN, low-dose GQYS (GQYS-L, 5.2 g/kg), high-dose GQYS (GQYS-H, 10.4 g/kg), and Losartan (6.5 mg/kg). Coincident C57/BL6 mice were used as controls. Periodic acid-Schiff (PAS) staining, biochemical analyses, and immunofluorescence (IF) were used for therapeutic evaluation. Network pharmacology and transcriptomic analyses were performed to investigate the potential mechanisms of GQYS, while Western blotting and IF were performed to confirm these actions. Results: Compared to the model group, 24 h proteinuria and alanine aminotransferase levels were significantly reduced in the GQYS groups. PAS staining showed that IgAN mice exhibited glomerular mesangial hypercellularity as well as matrix expansion, whereas these pathologies were alleviated in the GQYS groups. IF results revealed that GQYS reduced deposition of IgA and C3 in the glomerular mesangial areas compared to that in the model mice. Network pharmacology and transcriptomic analyses identified genes and pathways that may be associated with the effects of GQYS against IgAN. Western blotting and IF results indicated GQYS attenuated the expression of TLR4/MyD88/NF-kB and IL-6/JAK2/STAT3 signaling pathway related proteins. Conclusion: GQYS reduced proteinuria and ameliorate renal pathological damage in IgAN via TLR4/MyD88/NF-kB and IL-6/JAK2/STAT3 signaling, offering a promising therapeutic strategy.
- Open Access
- 7 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1493521
Clinical characteristics and prognostic analysis of patients with type 2 diabetic kidney disease and non-diabetic kidney disease
Background: In diabetic patients, non-diabetic kidney disease (NDKD) may occur independently or alongside diabetic kidney disease (DKD). This study explored the utility of kidney biopsy in type 2 diabetes mellitus (T2DM) patients and the predictability of diagnosing DKD combined with NDKD using clinical and laboratory data.Methods: This retrospective study examines medical records of T2DM patients who underwent percutaneous renal biopsy at Hangzhou TCM Hospital, Zhejiang Chinese Medical University, from 2012 to 2023. The patient’s demographic, clinical, blood test and pathological examination data were retrieved from their medical records. Multivariate regression analysis evaluated predictive factors for NDKD superimposed on DKD (DKD+NDKD).Results: A total of 285 patients were analyzed. The average age at the time of renal biopsy was 53.26 ± 10.55 years. The duration of diabetes was 93.19 ± 70.78 months. Of the patient population, 35.44% (101/285) were diagnosed with DKD alone, while 64.56% (184/285) had DKD+NDKD. Immunoglobulin A nephropathy was the most common pathological type in the DKD+NDKD group, accounting for 37.30% of the patients. Cystatin C [HR=2.688, 95% CI 1.035-6.879, P < 0.05] independently predicted the prognosis of patients with DKD+NDKD.Conclusions: These findings suggest that cystatin C plays a role in influencing the prognosis of patients with DKD + NDKD, indicating that NDKD patients might require distinct treatment strategies compared to those with DKD alone. However, further prospective clinical trials are needed to provide more clarity on the prognosis and outcomes of diabetic patients.
- 7 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1493521
Open AccessClinical characteristics and prognostic analysis of patients with type 2 diabetic kidney disease and non-diabetic kidney disease
Background: In diabetic patients, non-diabetic kidney disease (NDKD) may occur independently or alongside diabetic kidney disease (DKD). This study explored the utility of kidney biopsy in type 2 diabetes mellitus (T2DM) patients and the predictability of diagnosing DKD combined with NDKD using clinical and laboratory data.Methods: This retrospective study examines medical records of T2DM patients who underwent percutaneous renal biopsy at Hangzhou TCM Hospital, Zhejiang Chinese Medical University, from 2012 to 2023. The patient’s demographic, clinical, blood test and pathological examination data were retrieved from their medical records. Multivariate regression analysis evaluated predictive factors for NDKD superimposed on DKD (DKD+NDKD).Results: A total of 285 patients were analyzed. The average age at the time of renal biopsy was 53.26 ± 10.55 years. The duration of diabetes was 93.19 ± 70.78 months. Of the patient population, 35.44% (101/285) were diagnosed with DKD alone, while 64.56% (184/285) had DKD+NDKD. Immunoglobulin A nephropathy was the most common pathological type in the DKD+NDKD group, accounting for 37.30% of the patients. Cystatin C [HR=2.688, 95% CI 1.035-6.879, P < 0.05] independently predicted the prognosis of patients with DKD+NDKD.Conclusions: These findings suggest that cystatin C plays a role in influencing the prognosis of patients with DKD + NDKD, indicating that NDKD patients might require distinct treatment strategies compared to those with DKD alone. However, further prospective clinical trials are needed to provide more clarity on the prognosis and outcomes of diabetic patients.
- 12 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 2) , 113554
Corrigendum to “Identification and validation of diagnostic markers related to immunogenic cell death and infiltration of immune cells in diabetic nephropathy” [Int. Immunopharmacol. 143(Pt 1) (2024) 113236]
- 12 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 2) , 113554
Corrigendum to “Identification and validation of diagnostic markers related to immunogenic cell death and infiltration of immune cells in diabetic nephropathy” [Int. Immunopharmacol. 143(Pt 1) (2024) 113236]
- 7 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 1) , 113236
Identification and validation of diagnostic markers related to immunogenic cell death and infiltration of immune cells in diabetic nephropathy
- 7 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 1) , 113236
Identification and validation of diagnostic markers related to immunogenic cell death and infiltration of immune cells in diabetic nephropathy
- Open Access
- 10 April 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 5149-5150
A commentary on ‘Safety and efficacy of kidney transplantation in patients with aortoiliac stenosis: a retrospective cohort study’
An abstract is unavailable. This article is available as a PDF only.
- 10 April 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 5149-5150
Open AccessA commentary on ‘Safety and efficacy of kidney transplantation in patients with aortoiliac stenosis: a retrospective cohort study’
An abstract is unavailable. This article is available as a PDF only.
- RetractedOpen Access
- 1 February 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 739-757
Network Pharmacology, Molecular Docking, and Experimental Verification to Reveal the Mitophagy-Associated Mechanism of Tangshen Formula in the Treatment of Diabetic Nephropathy
Purpose: This study investigated the mechanism of TSF in treating DN through network pharmacology, molecular docking, and experimental validation. Methods: To identify critical active ingredients, targets, and DN genes in TSF, multiple databases were utilized for screening purposes. The drug-compound-target network was constructed using Cytoscape 3.9.1 software for network topological analysis. The protein interaction relationship was analyzed using the String database platform. Metascape database conducted enrichment analysis on the key targets using Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. The renoprotective effect was evaluated using a mouse model of diabetic nephropathy (db/db mice) that occurred spontaneously. Validation of the associated targets and pathways was performed using Western Blot (WB), Polymerase Chain Reaction (PCR), and Immunohistochemical methods (IHC). Results: The network analysis showed that the TSF pathway network targeted 24 important targets and 149 significant pathways. TSF might have an impact by focusing on essential objectives such as TP53, PTEN, AKT1, BCL2, BCL2L1, PINK-1, PARKIN, LC3B, and NFE2L2, along with various growth-inducing routes. Our findings demonstrated that TSF effectively repaired the structure of mitochondria in db/db mice. TSF greatly enhanced the mRNA levels of PINK-1. WB and IHC findings indicated that TSF had a notable impact on activating the PINK-1/PARKIN signaling pathway in db/db mice, significantly increasing LC3 and NRF2 expression. Conclusion: Our results indicate that TSF effectively addresses DN by activating the PINK-1/PARKIN signaling pathway and enhancing Mitochondrion structure in experimental diabetic nephropathy.
- 1 February 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 739-757
RetractedOpen AccessNetwork Pharmacology, Molecular Docking, and Experimental Verification to Reveal the Mitophagy-Associated Mechanism of Tangshen Formula in the Treatment of Diabetic Nephropathy
Purpose: This study investigated the mechanism of TSF in treating DN through network pharmacology, molecular docking, and experimental validation. Methods: To identify critical active ingredients, targets, and DN genes in TSF, multiple databases were utilized for screening purposes. The drug-compound-target network was constructed using Cytoscape 3.9.1 software for network topological analysis. The protein interaction relationship was analyzed using the String database platform. Metascape database conducted enrichment analysis on the key targets using Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. The renoprotective effect was evaluated using a mouse model of diabetic nephropathy (db/db mice) that occurred spontaneously. Validation of the associated targets and pathways was performed using Western Blot (WB), Polymerase Chain Reaction (PCR), and Immunohistochemical methods (IHC). Results: The network analysis showed that the TSF pathway network targeted 24 important targets and 149 significant pathways. TSF might have an impact by focusing on essential objectives such as TP53, PTEN, AKT1, BCL2, BCL2L1, PINK-1, PARKIN, LC3B, and NFE2L2, along with various growth-inducing routes. Our findings demonstrated that TSF effectively repaired the structure of mitochondria in db/db mice. TSF greatly enhanced the mRNA levels of PINK-1. WB and IHC findings indicated that TSF had a notable impact on activating the PINK-1/PARKIN signaling pathway in db/db mice, significantly increasing LC3 and NRF2 expression. Conclusion: Our results indicate that TSF effectively addresses DN by activating the PINK-1/PARKIN signaling pathway and enhancing Mitochondrion structure in experimental diabetic nephropathy.